Search Login Register

Gemfibrozil (Lopid) Summary

Description: A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established.

Also Known As: Lopid; 1A Brand of Gemfibrozil; Alphapharm Brand of Gemfibrozil; Apo-Gemfibrozil; Apotex Brand of Gemfibrozil Show All >>

Networked: 541 relevant articles (67 outcomes, 140 trials/studies) for this Drug

Key Diseases for which Gemfibrozil is Relevant

  1. Coronary Disease (Coronary Heart Disease) : 9 outcomes 31 studies in 54 results
  2. Hyperlipidemias (Hyperlipidemia) : 9 outcomes 13 studies in 75 results
  3. Hypertriglyceridemia : 9 outcomes 8 studies in 62 results
  4. Hyperlipoproteinemias : 6 outcomes 4 studies in 27 results
  5. Dyslipidemias (Dyslipidemia) : 5 outcomes 6 studies in 36 results
Show All >>

Drugs Related to Gemfibrozil

  1. HDL Cholesterol
  2. Triglycerides (Triacylglycerol)
  3. Lovastatin (Mevacor)
  4. Fibric Acids (Fibrates)
  5. Lipoproteins (Lipoprotein)
  6. LDL Cholesterol
  7. Bezafibrate
  8. Simvastatin (Zocor)
  9. Clofibrate
  10. Insulin (Novolin)
Show All >>

Therapies Related to Gemfibrozil

  1. Transplantation (Transplant Recipients)
  2. Continuous Ambulatory Peritoneal Dialysis (CAPD)
  3. Homologous Transplantation (Allograft)
  4. Phototherapy (Light Therapy)
  5. Transplants (Transplant)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.